Alzheimer Disease Clinical Trials

135 studies are recruiting for alzheimer disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease

   An open label pilot study in mild to moderate AD patients to assess the effects of treatment with ECHS AD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days.…

   Stage

   Not phased

   Ages

   50 to 100

   Site

   Hackensack Medical Center, Hackensack, New Jersey

   Run by

   Herrick Medical LLC

   See if you can join NCT05295615 on ClinicalTrials.gov

2. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

   The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who c…

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Imaging Endpoints, Scottsdale, Arizona

   Locations

   252 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06937229 on ClinicalTrials.gov

3. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Imaging Endpoints, Scottsdale, Arizona

   Locations

   162 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011732 on ClinicalTrials.gov

4. Making Connections Thru Music

   Healthcare systems around the world, including within the United States, have long-established shortages of trained caregivers. The American Health Care Association states that "the health care system has experienced a shortage of trained caregivers for critical roles for some time." This scarcity …

   Stage

   Not phased

   Ages

   18 to 103

   Site

   Hopeful Aging, Winchester, Massachusetts

   Locations

   2 in total

   Run by

   Hopeful Aging

   See if you can join NCT06079216 on ClinicalTrials.gov

5. The BRAIN App (Phase 2 SBIR)

   There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S. More than half of LTC residents have some form of dementia (Alzheimer's Associat…

   Stage

   Not phased

   Ages

   65 and older

   Site

   Hopeful Aging, Winchester, Massachusetts

   Run by

   Hopeful Aging

   See if you can join NCT06298474 on ClinicalTrials.gov

6. Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

   This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P…

   Stage

   Phase 2

   Ages

   55 to 80

   Site

   Banner Alzheimer's Institute, Phoenix, Arizona

   Locations

   38 in total

   Run by

   Lighthouse Pharmaceuticals, Inc.

   See if you can join NCT06847321 on ClinicalTrials.gov

7. The Role of the Locus Coeruleus in Age-related Distractibility

   A growing body of research has highlighted the importance of frontal regions, at both the functional and structural levels, in age-related declines in attentional and cognitive processing. However, the underlying neurobiological pathophysiological changes in the brain that contribute to these decli…

   Stage

   Not phased

   Ages

   18 to 75

   Site

   Virginia Polytechnic Institute and State University, Blacksburg, Virginia

   Run by

   Virginia Polytechnic Institute and State University

   See if you can join NCT05574634 on ClinicalTrials.gov

8. Study to Understand Novel Biomarkers in Researching Dementia

   The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and pr…

   Stage

   Not phased

   Ages

   60 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT06547099 on ClinicalTrials.gov

9. Alzheimer's Disease Genetics Study

   The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multipl…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Participants are being recruited from all over the United States, Nationwide, Indiana

   Run by

   Indiana University

   See if you can join NCT00064870 on ClinicalTrials.gov

10. Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

    The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are t…

    Stage

    Not phased

    Ages

    70 and older

    Site

    Saddleback Medical Center, Orange, California

    Locations

    7 in total

    Run by

    University of Michigan

    See if you can join NCT05929703 on ClinicalTrials.gov

11. Alzheimer's Tau Platform: Master Protocol

    The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. This platform trial …

    Stage

    Phase 2

    Ages

    50 to 80

    Site

    University of California, San Francisco, San Francisco, California

    Locations

    3 in total

    Run by

    Paul S. Aisen

    See if you can join NCT06957418 on ClinicalTrials.gov

12. Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

    This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve qual…

    Stage

    EARLY_Phase 1

    Ages

    18 to 85

    Site

    Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland

    Run by

    Johns Hopkins University

    See if you can join NCT04123314 on ClinicalTrials.gov

13. Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)

    The goal of this clinical trial is to learn if using large-coil (or "deep") repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus and surrounding areas is feasible, tolerable, and potentially efficacious for memory in Alzheimer's Disease. Previous work studying rTMS in Alzheim…

    Stage

    Phase 1

    Ages

    55 to 100

    Site

    UCLA TMS Clinical and Research Service, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT06597942 on ClinicalTrials.gov

14. A Study of LY3439539 in Participants With Alzheimer's Disease

    The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month.

    Stage

    Phase 1

    Ages

    50 to 85

    Site

    Austin Health - Heidelberg Repatriation Hospital, Ivanhoe,

    Locations

    11 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07598370 on ClinicalTrials.gov

15. ADRC Clinical Cohort (Alzheimer's Disease)

    The purpose of the study is to establish a clinical cohort for the Duke/UNC Alzheimer's Disease Research Center (ADRC). The cohort will be composed of subjects ages 25 to 44 at enrollment with normal cognition and subjects ages 45 to 80 at enrollment with normal cognition, mild cognitive impairment…

    Stage

    Not phased

    Ages

    25 to 80

    Site

    Duke University, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT06703541 on ClinicalTrials.gov

16. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

    This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

    Stage

    Phase 2

    Ages

    55 to 90

    Site

    University of Alabama - Huntsville Regional Medical Campus, Huntsville, Alabama

    Locations

    78 in total

    Run by

    Celgene

    See if you can join NCT06808984 on ClinicalTrials.gov

17. A Study of AMDX-2011P in Participants With Alzheimer's Disease

    The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Associated Retina Consultants, Phoenix, Arizona

    Run by

    Amydis Inc.

    See if you can join NCT06514001 on ClinicalTrials.gov

18. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

    Stage

    Phase 2

    Ages

    55 and older

    Site

    Advanced Research Center, Inc, Anaheim, California

    Locations

    67 in total

    Run by

    Intra-Cellular Therapies, Inc.

    See if you can join NCT06540833 on ClinicalTrials.gov

19. A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

    The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

    Stage

    Phase 4

    Ages

    50 and older

    Site

    ATP Clinical Research, Inc - Orange, Orange, California

    Locations

    14 in total

    Run by

    Alpha Cognition, Inc

    See if you can join NCT07633470 on ClinicalTrials.gov

20. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

    Stage

    Phase 3

    Ages

    55 to 90

    Site

    Gilbert Neurology Partners - PLLC - Avacare, Gilbert, Arizona

    Locations

    293 in total

    Run by

    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT06585787 on ClinicalTrials.gov

21. A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

    The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of…

    Stage

    Phase 1

    Ages

    50 to 85

    Site

    K2 Medical Research, LLC, Maitland, Florida

    Locations

    10 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06297590 on ClinicalTrials.gov

22. Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

    The objective of this investigational device exemption (IDE) study is to evaluate the safety and feasibility of using the Symani System and microsurgical techniques in the deep cervical lymph node (dCLN) region in the setting of mild to moderate Alzheimer's disease and lymphatic abnormalities.

    Stage

    Not phased

    Ages

    50 and older

    Site

    Stanford Medical Center, Palo Alto, California

    Locations

    3 in total

    Run by

    MMI (Medical Microinstruments, Inc.)

    See if you can join NCT07178210 on ClinicalTrials.gov

23. AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

    This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological tau, in participants with preclinical Alzheimer's disease. Up to 48 cog…

    Stage

    Phase 1

    Ages

    65 to 80

    Site

    Comprehensive Center for Brain Health, Boca Raton, Florida

    Locations

    6 in total

    Run by

    Institute for Molecular Medicine

    See if you can join NCT07158905 on ClinicalTrials.gov

24. Senicapoc in Alzheimer's Disease

    Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity …

    Stage

    Phase 2

    Ages

    55 to 85

    Site

    University of California, Davis Alzheimer's Disease Center, Sacramento, California

    Locations

    2 in total

    Run by

    University of California, Davis

    See if you can join NCT04804241 on ClinicalTrials.gov

25. Establishing Normal Cognitive Test Scores for Adults Using a Voice-Enabled Digital Testing Platform Across the Lifespan

    Trial weblink: https://www.memoryexam.com/job/norms/ Participants enrolled in this study will complete a single-session, non-invasive, computerized cognitive assessment administered through a secure, web-based digital platform. The purpose of the study is to establish normative cognitive performanc…

    Stage

    Not phased

    Ages

    18 to 100

    Site

    The Neurology Center of Southern California, Carlsbad, California

    Run by

    The Neurology Center of Southern California

    See if you can join NCT07763392 on ClinicalTrials.gov